ICML 2021 | Treating Burkitt lymphoma in adult patients
Ann LaCasce, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA, describes treatment regimens for adult patients with Burkitt lymphoma. Burkitt lymphoma is a rare and aggressive form of lymphoma in adults and current treatment regimens include Hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and cytarabine), EPOCH-R (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), and the modified Magrath regimen (cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, and cytarabine). Patients with central nervous system (CNS) or bone marrow involvement require more intensive treatment such as the modified Magrath regimen and patients with HIV can receive similar treatment and will have comparable outcomes. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
